Corcept Therapeutics (CORT) is a US-listed Healthcare company in Medical - Pharmaceuticals with a market capitalization of
0.0B, trading at $93.28 on the NASDAQ. This SniperIQ fundamentals page covers Corcept Therapeutics's valuation (P/E 207.3x, P/B 15.3x), profitability (net margin 6.2%), revenue ($761M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Market Cap
0.0B
P/E (TTM)207.3x
Net Margin6.2%
Revenue (FY25)$761M
Full research coverage
8-Quarter Revenue & Margin Trend
Debt Maturity & Coverage
Peer Valuation Comparison
Free Cash Flow & Owner Earnings
AI Signal + Institutional Flow
DCF Valuation Model
Frequently Asked Questions
What is Corcept Therapeutics's market cap?
Corcept Therapeutics (CORT) has a market capitalization of approximately
0.0B, trading at $93.28 on the NASDAQ. Market cap moves with the live share price.
What is Corcept Therapeutics's P/E ratio?
Corcept Therapeutics's trailing twelve-month P/E ratio is 207.3x, with a price-to-book (P/B) of 15.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Corcept Therapeutics?
Corcept Therapeutics runs a net profit margin of 6.2%, a gross margin of 98.3%, and an operating margin of -1.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Corcept Therapeutics generate?
Corcept Therapeutics reported revenue of $761M for fiscal year 2025, with net income of
00M and earnings per share (EPS) of 0.95. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Corcept Therapeutics pay a dividend?
Corcept Therapeutics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Corcept Therapeutics financially healthy?
Corcept Therapeutics carries a debt-to-equity ratio of 0.02x and a current ratio of 2.86x, with a market beta of 0.46. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Corcept Therapeutics a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Corcept Therapeutics (CORT) the key facts are: market cap
0.0B, P/E 207.3x, revenue $761M, 52-week range 28.66-95.79. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Corcept Therapeutics's full fundamentals live
Get Corcept Therapeutics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.